Durable response to ALK inhibition in low-allele-frequency SPTBN1–ALK–rearranged gastric cancer followed by lineage plasticity–mediated resistance: a case report

• by Zihua Guan, Jiao Liu, Wenlu Yu, Xu Wang, Xinmei Zhang

• July 21, 2026

2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

• July 2, 2026

• 1 min

Surviving CGT's Funding Winter

In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market

• by Alun Evans, James Strachan

• July 15, 2026

• 11 min

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

• June 26, 2026

• 1 min